Please assess the completion status of the following clinical trial:

Trial Title: Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 12.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteer between 60-90 days old, 6-12 years old, or 18-49 years old;~* Healthy volunteers who fulfill all the required conditions for receiving the investigational vaccine as established by medical history and clinical examination and determined by investigators;~* Proven legal identity;~* Participants (≥ 18 years old), or guardians of the participants (\< 18 years old) should be capable of understanding the written consent form, and such form should be signed prior to enrolment;~* Complying with the requirement of the study protocol;~* Axillary temperature ≤ 37.0 °C;~Exclusion Criteria:~* Breast feeding, pregnant, or expected to conceive in the next 60 days;~* History of allergy to any vaccine, or any ingredient of the vaccine, or serious adverse reaction(s) to vaccination, such as urticaria, dyspnea, angioneurotic edema, abdominal pain, etc;~* Congenital malformation, developmental disorders, genetic defects, or severe malnutrition;~* Autoimmune disease or immunodeficiency/immunosuppressive;~* serious chronic diseases, serious cardiovascular disease, hypertension or diabetes that cannot be stabilized by medication, liver or kidney disease, malignancy, etc;~* severe nervous system disease (epilepsy, seizures or convulsions) or mental illness;~* History of thyroidectomy, asplenia, functional asplenia, or any condition resulting in the absence or removal the spleen;~* Bleeding disorder diagnosed by a doctor (e.g., coagulation factor deficiency, coagulation disorder, or platelet disorder) , or significant bruising or coagulopathy;~* Long term history of alcoholism or drug abuse;~* Receipt of any of the following products:~  1. Any subunit or inactivated vaccine within the past 7 day;~ 2. Any live attenuated vaccine within the past 14 days;~ 3. Any other investigational medicine(s) within the past 30 days;~ 4. Any blood product within the past 3 months;~ 5. Any immunosuppressant, cytotoxic medications, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) within the past 6 month prior to study entry;~* Acute illness or acute exacerbation of chronic disease within the past 7 days;~* Axillary temperature \> 37.0 °C;~* Infant participants with prior vaccination of poliovirus;~* Any other factor that, in the judgment of the investigator, suggesting the volunteer is unsuitable for this study;

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Phase I Adult Group - High dosage (Type: EXPERIMENTAL): * Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~* Intervention: Single-dose regimen of high dosage investigational sIPV
- Phase I Adult Group - Medium dosage (Type: EXPERIMENTAL): * Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~* Intervention: Single-dose regimen of medium dosage investigational sIPV
- Phase I Child Group - High dosage (Type: EXPERIMENTAL): * Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~* Intervention: Single-dose regimen of high dosage investigational sIPV
- Phase I Child Group - Medium dosage (Type: EXPERIMENTAL): * Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~* Intervention: Single-dose regimen of medium dosage investigational sIPV
- Phase I Infant Group - High dosage (Type: EXPERIMENTAL): * Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~* Intervention: Three-dose regimen of high dosage investigational sIPV
- Phase I Infant Group - Medium dosage (Type: EXPERIMENTAL): * Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~* Intervention: Three-dose regimen of medium dosage investigational sIPV
- Phase I Infant Group - Low dosage (Type: EXPERIMENTAL): * Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~* Intervention: Three-dose regimen of low dosage investigational sIPV
- PhaseⅡExperimental Group - High dosage (Type: EXPERIMENTAL): * Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~* Intervention: Three-dose regimen of high dosage investigational sIPV
- PhaseⅡExperimental Group - Medium dosage (Type: EXPERIMENTAL): * Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~* Intervention: Three-dose regimen of medium dosage investigational sIPV
- PhaseⅡExperimental Group - Low dosage (Type: EXPERIMENTAL): * Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~* Intervention: Three-dose regimen of low dosage investigational sIPV
- PhaseⅡControl Group -commercialized sIPV (Type: ACTIVE_COMPARATOR): * Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~* Intervention:Three-dose regimen of commercialized sIPV
- PhaseⅡ Control Group -commercialized IPV (Type: ACTIVE_COMPARATOR): * Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~* Intervention: Three-dose regimen of commercialized IPV

Based on this trial design, predict the completion outcome and termination type (if applicable).